Tags : Immunotherapy

Roche’s Tecentriq (atezolizumab) Receives MHLW’s Approval as the First Immunotherapy

Shots: The approval is based on P-I/III IMpower133 study assessing Tecentriq (1200mg, IV,) + CT (carboplatin and etoposide) q3w over 60mins., if tolerated subsequent infusion can be administered over 30mis. vs CT as monothx. in patients with extensive-stage small-cell lung cancer The P-I/III IMpower133 study results: median OS (12.3 vs 10.3mos.); m-PFS (5.2 vs 4.3mos.); […]Read More

Immunotherapy Keytruda Exceeds Opdivo in Q2 sales

Shots:  Keytruda sold $1.67Bn, 90% Y-o-Y, narrowly beating Opdivo’s $1.63Bn in Q2’18  Higher sales are observed as Keytruda in combination with Lilly’s Alimta and platinum chemo improves OS with 51% reduction in death in NSCLC patient vs chemo Above combination is showing immense attraction from Physicians despite of pending FDA approval Click here to read […]Read More